For Severe Asthma, Most Surveyed U.S. Payers Would Reimburse a Novel Premium-Priced Therapy Offering a Substantially Greater Reduction in Exacerbations than Xolair Reduction in Exacerbations Remains the Top Driver of Physician Prescribing Choice in Modera
BURLINGTON, Mass., May 1, 2014 /PRNewswire/ -- Decision Resources Group finds that 90 percent of surveyed U.S. payers indicated a willingness to pay a premium-price for a novel therapy with substantially greater improvements in reducing exacerbations than Genentech/Novartis's Xolair in the treatment of severe asthma. Surveyed U.S. and European pulmonologists agree that reduction in rate of exacerbations is the attribute that most influences prescribing decisions in moderate to severe asthma. Clinical data and the opinions of interviewed thought leaders indicate that GlaxoSmithKline's Bosatria and Roche/Genentech/Chugai's lebrikizumab have a potential to partially fulfill this unmet need.
Other key findings from the Decision Base report entitled
Comments from Decision Resources Group Analyst Eun-Jin Yang, Ph.D.:
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.
Christopher Comfort 781-993-2597 email@example.com
SOURCE Decision Resources Group